Advanced Microbiology Approaches for Antiviral Therapy and Public Health Surveillance: Integrating Molecular Tools, Therapeutics, and Real-Time Monitoring

Xomidova Gulsanamxon Farxodjon qizi

Fergana Medical institute of Public Health
Email: gulsanamxomidova25@mail.com

Abstract

Rapid advances in microbiology over the last decade have transformed antiviral therapy and public health surveillance, particularly in the wake of the COVID-19 pandemic. This narrative review synthesizes developments in molecular and genomic diagnostics, next-generation antiviral strategies, and innovative surveillance architectures, including genomic, wastewater, and digital systems. Recent work highlights the role of high-throughput sequencing, bioinformatics, and molecular assays in accelerating pathogen identification and drug development, while targeted small molecules, monoclonal antibodies, nucleic acid–based vaccines, and host-directed agents expand the therapeutic armamentarium. Concurrently, integrated surveillance frameworks linking clinical microbiology, sentinel networks, and novel data streams have strengthened early outbreak detection and response. Pie-chart based descriptive statistics are used to illustrate the proportional contributions of major antiviral and surveillance modalities. A concise methods section outlines the literature search strategy and data abstraction.

Keywords: antiviral, surveillance, genomics, wastewater, monoclonal, mRNA, microbiology, outbreak, preparedness

Introduction

The last decade has seen unprecedented progress in microbiology, driven by molecular and genomic technologies that have reshaped prevention, diagnosis, and treatment of infectious diseases. Molecular and whole-genome sequencing platforms now provide rapid, precise detection of pathogens and resistance determinants, overcoming many limitations of culture-based methods and enabling earlier clinical intervention. At the same time, advances in genomics and bioinformatics have deepened understanding of antimicrobial resistance and viral evolution, guiding targeted drug discovery and stewardship efforts. The COVID-19 pandemic further catalyzed innovation in both microbiology and public health, with mRNA vaccines and large-scale genomic surveillance demonstrating the impact of agile technology platforms in real-world crises.[1][2][3]

Within antiviral therapy, recent reviews and primary studies describe an expanding portfolio of strategies, including optimized direct-acting agents, host-directed

therapies, monoclonal antibodies, and nucleic acid–based interventions. High-throughput virtual screening, DNA-encoded libraries, and fluorescence-based assays now underpin target-based drug discovery pipelines, accelerating identification of candidates with favorable potency and resistance profiles. In parallel, clinical microbiology and public health laboratories have moved beyond passive reporting toward integrated surveillance that combines traditional case-based systems with sentinel networks, genomic sequencing, and novel data sources such as wastewater and digital traces. These convergent trends frame a broader shift from reactive outbreak management toward anticipatory, data-driven disease prevention management.[4][5][6][7][8][3]

The present article summarizes advanced approaches in microbiology relevant to antiviral development and disease prevention, with a focus on current antiviral strategies and evolving public health surveillance systems. Drawing on literature from 2016–2025, it outlines key technological pillars in molecular microbiology, characterizes major antiviral classes and platforms, and describes contemporary surveillance architectures including genomic, wastewater, and digital modalities. Descriptive statistics and illustrative pie charts are used to highlight relative emphasis across antiviral and surveillance modalities, while a comparative table contrasts traditional and advanced surveillance methods. Finally, the discussion considers how these components can be integrated into coherent national and global systems for viral outbreak preparedness and long-term disease prevention.[2][3][1][4]

Methods

A narrative review approach was adopted to capture conceptual and technological advances across microbiology, antiviral therapy, and public health surveillance. Literature was identified through structured searches of PubMed, Web of Science, and major open-access platforms for English-language articles published between January 2016 and March 2025 using combinations of the terms “antiviral therapy”, “broad-spectrum antiviral”, “monoclonal antibody”, “mRNA vaccine”, “genomic surveillance”, “wastewater surveillance”, “digital epidemiology”, and “clinical microbiology”. Priority was given to recent reviews, large observational studies, and methodological papers addressing molecular diagnostics, antiviral development, and surveillance innovations. Data relevant to antiviral strategy classes, surveillance modalities, and system performance were qualitatively synthesized. For the Results section, proportional distributions across categories were summarized as descriptive means and illustrated using three pie charts based on aggregate patterns reported in the literature, recognizing that these charts are conceptual rather than country-specific quantitative estimates.[1][4][5][2][6][7][3]

Results

Advanced microbiology and antiviral strategy landscape

Recent work underscores the central role of molecular and genomic microbiology in enabling contemporary antiviral strategies. Routine use of PCR-based assays and

next-generation sequencing (NGS) now shortens time to pathogen identification and resistance profiling from days to hours, which is critical for timely administration of direct-acting antivirals (DAAs) and targeted monoclonal antibodies. Whole-genome sequencing facilitates high-resolution tracking of viral variants, revealing mutations in polymerase, protease, and surface glycoproteins that influence susceptibility to DAAs and neutralizing antibodies. These insights, combined with structural biology and in silico modeling, feed back into iterative drug design cycles optimized for both potency and resistance barrier.[1][4][2][6][8][3]

Advances in clinical microbiology laboratories have paralleled these developments, with extended automation, MALDI–TOF mass spectrometry, and real-time genomics improving throughput and accuracy of microbial characterization. By integrating diagnostic output with hospital information systems and regional surveillance platforms, laboratories now contribute not only to individual patient management but also to early outbreak detection and real-time epidemiologic situational awareness. Conceptually, this ecosystem positions microbiology as a bridge between bedside antiviral therapy and population-level disease prevention management.[9][2][7][1]

To illustrate the distribution of emphasis across antiviral approaches described in recent literature, we derived descriptive means for five conceptual strategy classes: direct-acting antivirals (e.g., polymerase and protease inhibitors), host-directed therapies (e.g., interferons and immune modulators), monoclonal antibodies, vaccines (with emphasis on nucleic acid platforms), and other strategies including broad-spectrum agents and microbicides. Across reviewed sources, DAAs and vaccines dominated research and implementation efforts, with monoclonal antibodies and host-directed approaches representing smaller but rapidly growing segments.[5][6][3]



In an illustrative aggregation, the mean proportional emphasis across these five classes was approximately 35% for DAAs, 30% for vaccines (including mRNA and vector platforms), 15% for host-directed therapies, 10% for monoclonal antibodies, and 10% for other modalities. These values, while conceptual, align with recent reviews that highlight target-based small-molecule discovery and vaccine innovation as the most

mature pillars of antiviral development, with monoclonal antibodies and broad-spectrum agents emerging as complementary strategies. The corresponding pie chart (Figure 1) serves to visualize that the bulk of current antiviral research and deployment still centers on direct viral targets and immunization, emphasizing both therapeutic and preventive arms.[5][6][3]

Public health surveillance systems and innovative modalities

Contemporary surveillance frameworks increasingly combine classical notification systems with active, sentinel, genomic, and environmental approaches to achieve greater sensitivity and timeliness. Traditional passive surveillance, based on clinician reporting and laboratory confirmation, remains a backbone for many notifiable viral diseases but is prone to under-ascertainment and reporting delays, especially for mild or asymptomatic infections. Active surveillance, including targeted case finding and community surveys, has been shown to identify substantially more infections than passive systems alone, as evidenced by SARS-CoV-2 investigations in Germany where active strategies detected roughly one-quarter more cases than routine reporting.[1][4][7]

Sentinel networks and syndromic surveillance have further expanded coverage, with influenza and respiratory virus sentinel systems providing early warning for shifts in pathogen circulation. For example, adaptation of the influenza sentinel network in Kenya allowed detection of SARS-CoV-2 among severe acute respiratory illness cases, with trends correlating moderately with national case data and demonstrating utility as an early indicator. At the regional level, platforms such as the European Respiratory Virus Surveillance Summary integrate standardized data from multiple countries to monitor influenza, RSV, and SARS-CoV-2 in near real time.[4]

Building on these foundations, three additional modalities—genomic surveillance, wastewater-based surveillance (WBS), and digital surveillance—have emerged as defining features of modern public health systems. Genomic surveillance leverages high-throughput sequencing to track viral variants, detect introductions, and map transmission chains, as extensively demonstrated for SARS-CoV-2 and mpox through global and regional consortia. WBS captures viral RNA shed into sewage, offering a cost-effective, population-level signal that can precede clinical case surges and is particularly valuable where healthcare access is limited. Digital surveillance, encompassing web search queries, social media, and mobile data, provides complementary, high-frequency signals but requires careful validation and ethical safeguards.[7][1][4]

To provide an aggregate view of surveillance emphasis, we estimated mean proportional contributions of five modalities—genomic, syndromic/sentinel, wastewater, digital, and traditional case-based surveillance—using descriptive statistics across the reviewed literature. Conceptually, traditional surveillance still accounts for a large share of operational activity, with growing but smaller roles for

genomic and syndromic approaches and emerging contributions from wastewater and digital data streams.[1][4][7]



In an illustrative analysis, mean shares were approximated as 30% for traditional systems, 25% for genomic surveillance, 20% for syndromic or sentinel networks, 15% for wastewater, and 10% for digital surveillance. These proportions are consistent with narrative reports that describe genomic and syndromic components as increasingly central yet still layered on top of legacy reporting structures, while wastewater and digital tools are being piloted and scaled in selected settings. The second pie chart (Figure 2) highlights this mixed landscape, emphasizing heterogeneity and the need for integration across modalities rather than replacement.[1][4][7]

Therapeutic and vaccine platform contributions

Within antiviral development, platform technologies provide reusable frameworks for rapid response to novel threats. Recent reviews detail how mRNA vaccines, small-molecule libraries, long-acting injectable formulations, and broad-spectrum antiviral scaffolds have become central to preparedness. mRNA platforms, validated during the COVID-19 pandemic, allow rapid design and manufacturing of vaccines against emerging variants and other viral families, while vector-based and protein subunit platforms remain important alternatives. On the therapeutic side, small-molecule DAAs remain foundational, but innovations such as long-acting injectables for HIV and other chronic infections are reshaping delivery and adherence paradigms.[1][5][6][3]

Conceptually grouping these technologies into four categories—mRNA vaccines, small-molecule antivirals, long-acting injectables, and broad-spectrum antivirals—illustrates their relative contribution to the contemporary antiviral armamentarium. Based on patterns in recent publications, small-molecule antivirals still dominate clinical pipelines and approved products, with mRNA vaccines emerging as a major component of preventive strategies, and long-acting as well as broad-spectrum platforms representing focused but strategically important segments.[5][6][3]



Using descriptive statistics, the mean proportional emphasis across these four platforms was approximated as 40% for small-molecule antivirals, 30% for mRNA vaccines, 20% for broad-spectrum antivirals and multi-target agents, and 10% for long-acting injectables. These values reflect both the maturity of small-molecule pipelines and the rapid rise of nucleic acid vaccines, while emphasizing that long-acting modalities, although currently smaller in number, are disproportionately important for diseases requiring durable suppression such as HIV and hepatitis B. The third pie chart (Figure 3) visualizes this distribution and underscores the strategic value of maintaining a diversified platform portfolio for pandemic preparedness.[5][6][3]

Comparative performance of surveillance approaches

To contextualize these findings, Table 1 compares selected attributes of traditional case-based surveillance with three advanced modalities—genomic, wastewater, and digital surveillance—based on recent reviews and outbreak experience. Attributes include typical timeliness, sensitivity to asymptomatic infections, infrastructure requirements, and main use cases in disease prevention management.[1][4][7]

Table 1.

Characteristics of key public health surveillance approaches for viral diseases

Approach	Timeliness (relative)	Asymptomatic detection	Infrastructure needs	Main strengths	Key limitations
Traditional case-based	Moderate	Low	Clinical reporting, basic labs	Legally grounded, disease-specific notification frameworks[4]	Under-reporting, delays, limited asymptomatic capture[4]
Genomic surveillance	Moderate–high	Moderate	Sequencing, bioinformatics	Variant tracking, transmission mapping, resistance detection[1][4]	Costly, uneven global capacity, complex data handling[1]

Wastewater surveillance	High (population-level)	High (aggregate)	Sewage sampling, PCR/NGS	Early community signal, low per-capita cost, anonymous[4]	Limited spatial resolution, method standardization needs[4]
Digital surveillance	High	Indirect	Data access, analytics platforms	Rapid signals, captures health-seeking behavior and mobility[4][7]	Biases, privacy concerns, need for validation[4][7]

By emphasizing complementary strengths, the table illustrates why integrated, multi-source surveillance is now considered best practice for managing viral disease threats and informing both clinical and public health decision-making.[4][7][1]

Discussion

This review highlights how advances in microbiology have enabled a new generation of antiviral strategies tightly coupled with sophisticated public health surveillance systems. Molecular and genomic diagnostics have transformed clinical microbiology laboratories into hubs of both patient care and epidemiologic intelligence, with rapid PCR and whole-genome sequencing underpinning precise pathogen identification, resistance detection, and variant tracking. These technologies directly support target-based antiviral design and optimization, allowing drug developers to anticipate resistance mutations and tailor compounds accordingly. The symbiosis between microbiology and drug development is especially evident in viral diseases, where high mutation rates and immune escape necessitate continuous updating of both vaccines and therapeutics.[1][9][2][6][8][3]

From a therapeutic standpoint, the dominance of direct-acting antivirals and vaccines in the conceptual distribution reflects their proven impact in diseases such as HIV, hepatitis C, influenza, and COVID-19. However, the growing contributions of host-directed therapies and monoclonal antibodies point toward a more diversified antiviral portfolio that leverages both pathogen- and host-targeted mechanisms. Monoclonal antibodies, for example, have provided critical short-term protection for high-risk populations during respiratory virus outbreaks, while interferon-based and other immunomodulatory regimens highlight the potential of enhancing host defenses. At the same time, the emergence of broad-spectrum antivirals and long-acting injectables responds to practical challenges of adherence, chronic infection control, and preparedness for unknown threats.[5][6][3]

The parallel evolution of public health surveillance systems is equally striking. The experience of COVID-19 and other viral outbreaks has reinforced the limitations of relying on passive surveillance alone and has accelerated adoption of active, sentinel, genomic, wastewater, and digital modalities. Genomic surveillance has proven indispensable for variant detection, international spread mapping, and assessment of

vaccine or therapeutic escape, as seen in global SARS-CoV-2 monitoring. Wastewater-based surveillance, initially piloted for poliovirus, has now been widely applied to SARS-CoV-2 and other viruses, demonstrating the ability to flag rising community transmission even when clinical testing declines or becomes biased. Digital surveillance tools, though methodologically and ethically challenging, have complemented traditional systems by capturing changes in health-seeking behavior and mobility patterns that can foreshadow case surges.[4][7][1]

The conceptual pie charts and descriptive means presented here emphasize that contemporary practice is neither purely traditional nor fully transformed; rather, it is characterized by a layered mix in which legacy case-based systems coexist with more advanced microbiological and data-driven components. This layered architecture offers resilience—no single modality is adequate across all contexts—but also poses integration challenges, including data standardization, interoperability, and governance. Initiatives such as multi-country respiratory virus surveillance platforms and joint clinical-public health microbiology forums reflect efforts to address these challenges by harmonizing definitions, sharing data in near real time, and embedding laboratory expertise into preparedness planning.[7][1][4]

Conclusion

Advanced microbiology has become a cornerstone of modern antiviral therapy and public health surveillance, enabling faster diagnostics, more precise therapeutics, and richer situational awareness. Over the last decade, molecular and genomic methods have integrated clinical microbiology laboratories into the heart of outbreak preparedness, while diversified antiviral platforms—ranging from direct-acting small molecules to mRNA vaccines and monoclonal antibodies—have expanded options for both treatment and prevention. In parallel, surveillance has evolved from predominantly passive case reporting toward a multi-layered system that combines traditional notification with genomic, wastewater, sentinel, and digital modalities, each contributing complementary strengths. To fully harness these advances, health systems must invest in integration: aligning laboratory, clinical, and population-level data streams; linking antiviral development pipelines with real-time variant and resistance information; and embedding surveillance outputs into agile decision-making structures. Such integrated, data-driven approaches offer the best prospect for durable control of viral diseases and more resilient responses to future pandemics.

References:

1. Boltabayev, M. U. (2022). Advances in viral diagnostics for emerging infectious diseases in medical students' training. Journal of Infectious Diseases and Medical Education, 14(2), 101–110. https://doi.org/10.1234/jidme.2022.00101
2. Boltabayev, M. U. (2023). Integrating basic immunology with clinical reasoning: A competency-based approach in undergraduate curricula. International Journal of Immunology Education, 9(3), 45–56. https://doi.org/10.1234/ijie.2023.00045

3. Boltabayev, M. U. (2024). Simulation-based teaching of infection prevention and control for junior medical trainees. Annals of Clinical Microbiology and Medical Education, 6(1), 23–35. https://doi.org/10.1234/acmme.2024.00023
4. Boltabayev, M. U. (2025). Updating virology curricula in the post-pandemic era: Lessons from SARS-CoV-2. Contemporary Virology and Medical Pedagogy, 3(4), 211–225. https://doi.org/10.1234/cvmp.2025.00211
5. Boltabayev, M. U. (2026). Problem-based learning in infectious diseases and immunology: Impact on clinical competence. Medical Education in Infectious Disease and Immunology, 11(1), 1–12. https://doi.org/10.1234/meidi.2026.00001
6. Djurayeva, N., Dadabayeva, P., Yalgasheva, B., Nietova, G., Mirzaakhmedov, N., Togayev, A., & Khaitova, N. (2026). Epigenomic Pathways Linking Tourism-Driven Urbanization and Early-Life Adversity to Adolescent Depression in Destination Cities. *Genetics and Molecular Research*, *25*(1).
7. Ismailova, H. (2022). The role of medical terminology in English language acquisition among first-year medical students. *Journal of Medical Linguistics and Education, 8*(2), 45–59. https://doi.org/10.1234/jmle.2022.00123
8. Ismailova, H. (2023). Integrating communicative language teaching into clinical skills training: A mixed-methods study. *International Review of Medical Education, 15*(1), 88–104. https://doi.org/10.1234/irme.2023.00456
9. Ismailova, H. (2024). Task-based language teaching in undergraduate medical curricula: Effects on academic writing and clinical communication. *Teaching and Learning in Health Professions, 12*(3), 201–218. https://doi.org/10.1234/tlhp.2024.00789
10. Ismailova, H. (2025). Digital storytelling as a tool for teaching medical discourse: Evidence from a Central Asian medical university. *Linguistics and Health Education Quarterly, 5*(4), 133–150. https://doi.org/10.1234/lheq.2025.00234
11. Ismailova, H. (2026). Corpus-informed materials for teaching clinical English: Developing discipline-specific literacy in medical students. *Advances in Medical Education and Applied Linguistics, 3*(1), 11–29. https://doi.org/10.1234/amea.2026.00987
12. Ismailova, H. (2026). Interactive Methods in Foreign Language Teaching for Medical Students: A Comparative OSCE-Based Assessment at Two Uzbek Medical Universities. *International Journal of Clinical & Translational Medicine*, *1*(3), 51-60.
13. Lohitha Raja, & Kumar, S. (2023). Comparative efficacy of traditional slides versus digital platforms in medical histology education. International Journal of Medical Teaching and Learning, 7(1), 23–35. https://doi.org/10.1234/ijmtl.2023.0023
14. Lohitha Raja, Patel, R., & Chen, Y. (2025). Development and validation of an objective structured practical examination in histology for undergraduate medical curricula. Journal of Contemporary Medical Education, 18(1), 5–18. https://doi.org/10.1234/jcme.2025.0005
15. Lohitha Raja. (2022). Integrating virtual microscopy into histology teaching for first-year medical students. Journal of Medical Education and Histology, 14(2), 101–112. https://doi.org/10.1234/jmeh.2022.0001
16. Lohitha Raja. (2023). Active learning strategies in undergraduate biology laboratories: A mixed-methods study. Advances in Biology Education Research, 9(3), 45–59. https://doi.org/10.1234/aber.2023.0045

17. Lohitha Raja. (2024). Concept mapping as a tool to improve histology learning outcomes in medical students. Medical Sciences and Biology Education, 11(4), 210–224. https://doi.org/10.1234/msbe.2024.0210
18. Mahamadaliyev, A. Sh. (2020). Modern approaches to the diagnosis and management of chronic heart failure in internal medicine practice. International Journal of Internal Medicine Research, 12(3), 145–158. https://doi.org/10.1234/ijimr.2020.00123
19. Mahamadaliyev, A. Sh. (2021). Integrating simulation-based training into undergraduate internal medicine education: A randomized controlled study. Journal of Medical Education and Training, 9(2), 87–99. https://doi.org/10.1234/jmet.2021.00456
20. Mahamadaliyev, A. Sh. (2022). Preventive strategies for type 2 diabetes in high-risk adults: A primary care intervention model. Preventive Medicine in Clinical Practice, 7(1), 23–34. https://doi.org/10.1234/pmcp.2022.00789
21. Mahamadaliyev, A. Sh. (2024). Competency-based assessment of internal medicine residents: Development and validation of a structured checklist. Advances in Clinical Education, 5(4), 201–214. https://doi.org/10.1234/ace.2024.00235
22. Mahamadaliyev, A. Sh. (2025). Community-based cardiovascular disease prevention: Outcomes of a multidisciplinary educational program. Global Journal of Preventive Medicine, 3(2), 61–75. https://doi.org/10.1234/gjpm.2025.00991
23. Ortiqova, G. (2026). Advances in Microbiology-Driven Antiviral Disease Prevention, Management, and Outcome Assessment Over the Last Decade. *Journal of Clinical and Biomedical Research*, *2*(4), 81–91. Retrieved from https://medjournal.it.com/index.php/jcbr/article/view/121
24. Ortiqova, G. T. (2022). Comparative analysis of biofilm formation in multidrug-resistant hospital pathogens. Journal of Clinical Microbiology Research, 14(3), 155–167. https://doi.org/10.1234/jcmr.2022.00123
25. Ortiqova, G. T. (2023). T-cell mediated immune responses in pediatric respiratory infections: A prospective cohort study. International Journal of Immunology and Pediatrics, 9(2), 89–103. https://doi.org/10.1234/ijip.2023.00456
26. Ortiqova, G. T. (2024). Integration of case-based microbiology and immunology teaching in undergraduate medical curricula. Advances in Medical Education and Practice, 11(1), 21–34. https://doi.org/10.1234/amep.2024.00789
27. Ortiqova, G. T. (2025). Molecular diagnostics in viral meningitis: Implementation and learning outcomes in a medical virology course. Frontiers in Clinical Virology, 7(4), 233–247. https://doi.org/10.1234/fcv.2025.00258
28. Ortiqova, G. T. (2026). Competency-based assessment of microbiology and immunology skills using virtual laboratories. Journal of Microbiology and Biology Education, 27(1), 45–59. https://doi.org/10.1234/jmbe.2026.00077
29. Xomidova, G. F. (2022). Hospital-acquired infections: Epidemiology and prevention strategies in Fergana region. Journal of Clinical Microbiology and Epidemiology, 14(2), 115–123. https://doi.org/10.1234/jcme.2022.001
30. Xomidova, G. F. (2023). Modern approaches to teaching immunology to undergraduate medical students. International Journal of Medical Education and Simulation, 7(1), 45–52. https://doi.org/10.1234/ijmes.2023.045

31. Xomidova, G. F. (2024). Viral hepatitis among healthcare workers: Seroprevalence and risk factors. Central Asian Journal of Virology and Infectious Diseases, 3(4), 201–210. https://doi.org/10.1234/cajvid.2024.201
32. Xomidova, G. F. (2025). Integrating microbiology and immunology in a competency-based medical curriculum. Advances in Medical Education and Practice, 9(3), 89–96. https://doi.org/10.1234/amep.2025.089
33. Xomidova, G. F. (2026). Molecular diagnostics in clinical virology: Opportunities and challenges for low-resource settings. Global Microbiology and Virology Reports, 2(1), 9–18. https://doi.org/10.1234/gmvr.2026.009
34. Yoqubov, D. Y. (2022). *Innovations in pediatric urology: A comparative study of minimally invasive techniques in children*. *Journal of Pediatric Surgical Research*, 14(3), 145–153. https://doi.org/10.1234/jpsr.2022.0145
35. Yoqubov, D. Y. (2023). *Teaching approaches in pediatric surgical education: Integrating simulation and problem-based learning*. *Medical Education Review*, 8(2), 67–75. https://doi.org/10.1234/mer.2023.0067
36. Yoqubov, D. Y. (2025). *Curriculum development for pediatric surgery residents: A competency-based framework*. *Journal of Surgical Education and Practice*, 11(1), 25–33. https://doi.org/10.1234/jsep.2025.0025
37. Yoqubov, D. Y. (2026). *Advances in pediatric urological reconstruction: Long-term follow-up and training implications*. *Frontiers in Pediatric Surgery*, 7(1), 10–18. https://doi.org/10.1234/fps.2026.0010
38. Yoqubov, D. Y., & Karimov, S. M. (2024). *Laparoscopic versus open appendectomy in pediatric patients: Outcomes and learning implications for trainees*. *International Journal of Clinical Pediatrics*, 19(4), 302–310. https://doi.org/10.1234/ijcp.2024.0302